Details of the Drug Reposition

General Information of This Drug (ID: DMZSD3T)

• Drug Name: Patient-derived CD19- and CD22 specific CAR (DMZSD3T)
• Drug Type: CAR T Cell Therapy

Information on Drug Reposition of This Drug

2 Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
leukaemia	DISS7D1V	2A60-2B33	Phase 1	[1]
Lymphoma	DISN6V4S	2A80-2A86	Phase 1	[1]

References

• [1] ClinicalTrials.gov (NCT03330691) A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia and Lymphoma